Opicapone Patent Expiration
Opicapone is Used for treating Parkinson's disease by providing adjunctive therapy to patients experiencing off episodes in combination with levodopa/carbidopa. It was first introduced by Amneal Pharmaceuticals Llc
Opicapone Patents
Given below is the list of patents protecting Opicapone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ongentys | US10357468 | Medicaments for slowing Parkinson's disease | May 27, 2035 | Amneal |
| Ongentys | US9630955 | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor | Dec 12, 2032 | Amneal |
| Ongentys | US12129247 | Administration regime for nitrocatechols | Jan 11, 2032 | Amneal |
| Ongentys | US10071085 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof | Mar 31, 2030 | Amneal |
| Ongentys | US10583130 | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof | Mar 31, 2030 | Amneal |
| Ongentys | US8524746 | Dosage regimen for COMT inhibitors | Jul 14, 2029 | Amneal |
| Ongentys | US8168793 | Nitrocatechol derivatives as COMT inhibitors | Apr 02, 2029 | Amneal |
| Ongentys | US9745290 | Dosage regimen for COMT inhibitors | Oct 10, 2027 | Amneal |
| Ongentys | US8907099 | Nitrocatechol derivatives as COMT inhibitors | May 12, 2027 | Amneal |
| Ongentys | US9550759 | Nitrocatechol derivatives as COMT inhibitors | Jul 26, 2026 | Amneal |
Opicapone's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List